K

Karyopharm Therapeutics
D

KPTI

0.86340
USD
0.09
(12.09%)
Market Open
Volume
4,615
EPS
-1
Div Yield
-
P/E
-1
Market Cap
108,196,544
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    177.01 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    154.89 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.88 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    104.43 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.585 USD
    More
News

Title: Karyopharm Therapeutics

Sector: Healthcare
Industry: Biotechnology
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuselarge B-cell lymphoma. The company derives its revenue from United States.